Heron Therapeutics (HRTX) Stock Forecast & Price Target

Heron Therapeutics is viewed positively because its commercial portfolio and hospital-focused pain and antiemetic products still offer meaningful operating leverage, while strong clinical results from Exparel further reinforce the attractiveness of the broader post-operative pain market. Management’s review of strategic alternatives could create upside, and a potential fit with Azurity is plausible given Azurity’s 2023 acquisition of Slayback and its expansion in acute care, though any transaction remains uncertain. Despite the CINVANTI patent setback and related cash-flow overhang, 2026 ZYNRELEF execution appears to be the key determinant of a recovery from depressed levels, supporting a constructive long-term view.

Heron Therapeutics is facing a weaker fundamental outlook because the adverse CINVANTI patent ruling threatens its largest revenue contributor, which was about 60% of topline and generated $42.3M of the company’s $72.4M in 1H26 revenue. With 2Q26 cash of $42.7M against about $142.7M of debt, and with 2026 revenue and Adjusted EBITDA guidance withdrawn, visibility into standalone cash runway and profitability has deteriorated materially. The slower-than-expected ZYNRELEF ramp, APONVIE’s small scale, paused 2H26 sales-force expansion, and strategic-alternatives process all underscore that the remaining portfolio may not offset CINVANTI erosion or support the business independently.